ACBD3 Bioinformatic Analysis and Protein Expression in Breast Cancer Cells
<i>ACBD3</i> overexpression has previously been found to correlate with worse prognosis for breast cancer patients and, as an incredibly diverse protein in both function and cellular localisation, ACBD3 may have a larger role in breast cancer than previously thought. This study further i...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-08-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/23/16/8881 |
_version_ | 1797444911454224384 |
---|---|
author | Jack Houghton-Gisby Rachel Kerslake Emmanouil Karteris Kefah Mokbel Amanda J. Harvey |
author_facet | Jack Houghton-Gisby Rachel Kerslake Emmanouil Karteris Kefah Mokbel Amanda J. Harvey |
author_sort | Jack Houghton-Gisby |
collection | DOAJ |
description | <i>ACBD3</i> overexpression has previously been found to correlate with worse prognosis for breast cancer patients and, as an incredibly diverse protein in both function and cellular localisation, ACBD3 may have a larger role in breast cancer than previously thought. This study further investigated ACBD3′s role in breast cancer. Bioinformatic databases were queried to characterise <i>ACBD3</i> expression and mutation in breast cancer and to investigate how overexpression affects breast cancer patient outcomes. Immunohistochemistry was carried out to examine ACBD3 location within cells and tissue structures. <i>ACBD3</i> was more highly expressed in breast cancer than in any other cancer or matched normal tissue, and expression over the median level resulted in reduced relapse-free, overall, and distant metastasis-free survival for breast cancer patients as a whole, with some differences observed between subtypes. IHC analysis found that ACBD3 levels varied based on hormone receptor status, indicating that ACBD3 could be a candidate biomarker for poor patient prognosis in breast cancer and may possibly be a biomarker for ER signal reprogramming of precancerous breast tissue. |
first_indexed | 2024-03-09T13:18:16Z |
format | Article |
id | doaj.art-3c001331312540a19117c0da174b546f |
institution | Directory Open Access Journal |
issn | 1661-6596 1422-0067 |
language | English |
last_indexed | 2024-03-09T13:18:16Z |
publishDate | 2022-08-01 |
publisher | MDPI AG |
record_format | Article |
series | International Journal of Molecular Sciences |
spelling | doaj.art-3c001331312540a19117c0da174b546f2023-11-30T21:32:34ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-08-012316888110.3390/ijms23168881ACBD3 Bioinformatic Analysis and Protein Expression in Breast Cancer CellsJack Houghton-Gisby0Rachel Kerslake1Emmanouil Karteris2Kefah Mokbel3Amanda J. Harvey4Centre for Genome Engineering and Maintenance, Institute for Health Medicine and Environments, Brunel University London, Uxbridge UB8 3PH, UKCentre for Genome Engineering and Maintenance, Institute for Health Medicine and Environments, Brunel University London, Uxbridge UB8 3PH, UKCentre for Genome Engineering and Maintenance, Institute for Health Medicine and Environments, Brunel University London, Uxbridge UB8 3PH, UKPrincess Grace Hospital, The London Breast Institute, London, W1U 5NY, UKCentre for Genome Engineering and Maintenance, Institute for Health Medicine and Environments, Brunel University London, Uxbridge UB8 3PH, UK<i>ACBD3</i> overexpression has previously been found to correlate with worse prognosis for breast cancer patients and, as an incredibly diverse protein in both function and cellular localisation, ACBD3 may have a larger role in breast cancer than previously thought. This study further investigated ACBD3′s role in breast cancer. Bioinformatic databases were queried to characterise <i>ACBD3</i> expression and mutation in breast cancer and to investigate how overexpression affects breast cancer patient outcomes. Immunohistochemistry was carried out to examine ACBD3 location within cells and tissue structures. <i>ACBD3</i> was more highly expressed in breast cancer than in any other cancer or matched normal tissue, and expression over the median level resulted in reduced relapse-free, overall, and distant metastasis-free survival for breast cancer patients as a whole, with some differences observed between subtypes. IHC analysis found that ACBD3 levels varied based on hormone receptor status, indicating that ACBD3 could be a candidate biomarker for poor patient prognosis in breast cancer and may possibly be a biomarker for ER signal reprogramming of precancerous breast tissue.https://www.mdpi.com/1422-0067/23/16/8881ACBD3breast cancerchromosome 1qpatient outcomes |
spellingShingle | Jack Houghton-Gisby Rachel Kerslake Emmanouil Karteris Kefah Mokbel Amanda J. Harvey ACBD3 Bioinformatic Analysis and Protein Expression in Breast Cancer Cells International Journal of Molecular Sciences ACBD3 breast cancer chromosome 1q patient outcomes |
title | ACBD3 Bioinformatic Analysis and Protein Expression in Breast Cancer Cells |
title_full | ACBD3 Bioinformatic Analysis and Protein Expression in Breast Cancer Cells |
title_fullStr | ACBD3 Bioinformatic Analysis and Protein Expression in Breast Cancer Cells |
title_full_unstemmed | ACBD3 Bioinformatic Analysis and Protein Expression in Breast Cancer Cells |
title_short | ACBD3 Bioinformatic Analysis and Protein Expression in Breast Cancer Cells |
title_sort | acbd3 bioinformatic analysis and protein expression in breast cancer cells |
topic | ACBD3 breast cancer chromosome 1q patient outcomes |
url | https://www.mdpi.com/1422-0067/23/16/8881 |
work_keys_str_mv | AT jackhoughtongisby acbd3bioinformaticanalysisandproteinexpressioninbreastcancercells AT rachelkerslake acbd3bioinformaticanalysisandproteinexpressioninbreastcancercells AT emmanouilkarteris acbd3bioinformaticanalysisandproteinexpressioninbreastcancercells AT kefahmokbel acbd3bioinformaticanalysisandproteinexpressioninbreastcancercells AT amandajharvey acbd3bioinformaticanalysisandproteinexpressioninbreastcancercells |